What happened with SNN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Smith & Nephew’s largest business is orthopaedics: it supplies joint implants, trauma products and technologies that help surgeons perform operations, including the CORI Surgical System for robotics-assisted surgery. Products for joint repair, ear, nose and throat procedures, and wound care also contribute substantial revenue, so the company is more than an implant maker.
Hospitals and outpatient surgery centres generally buy directly from the company in established markets, while distributors handle sales in emerging markets. Much of its wound-management business reaches customers through wholesalers and distributors, particularly for community and home care. Sales representatives and medical training help clinicians use its products; product sales, rather than services, generate nearly all revenue.
The US is its largest market. What customers can pay depends on healthcare budgets, reimbursement and procurement rules, including China’s volume-based purchasing programme, which puts pressure on prices. The company must also obtain product approvals and meet medical-device requirements to sell in each market; delays in certification can hold back product availability.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Smith+Nephew also faces sports medicine competition from privately held Arthrex and wound-care competition from Mölnlycke and ConvaTec, none of which appears in this list.
Stryker competes with Smith+Nephew across joint implants, robots that assist orthopedic surgery, trauma products, sports medicine and equipment for surgery inside joints. Its Orthopaedics sales are worth watching for joint-replacement and trauma demand; sports medicine products also put it up against Smith+Nephew’s joint-repair business.
Zimmer Biomet and Smith+Nephew compete for surgeons and hospitals buying joint implants, trauma products and robots that assist orthopedic surgery. Watch Zimmer Biomet’s new products and pricing: both help determine which supplier wins those customers.
Smith+Nephew is the primary challenger to Solventum in negative-pressure wound therapy, and the two also compete in advanced wound dressings. Watch Solventum’s wound-therapy products within MedSurg rather than its total sales for the clearest read on competition facing Smith+Nephew’s wound devices.
CONMED Corporation competes with Smith+Nephew in sports medicine implants and the systems that provide images, manage fluid and power instruments during surgery inside joints. Watch its orthopedic surgery sales rather than general surgery sales for a closer read on demand facing Smith+Nephew’s joint-repair and arthroscopic equipment businesses.
Johnson & Johnson competes with Smith+Nephew through DePuy Synthes and DePuy Mitek in joint implants, trauma and sports medicine products. News from those businesses is more directly relevant to Smith+Nephew than Johnson & Johnson’s prescription-medicine results.
Enovis Corporation and Smith+Nephew sell competing implants and instruments for joint replacement, limb reconstruction and foot and ankle surgery. Enovis’s Reconstructive sales are the relevant line to watch, rather than its non-surgical braces and rehabilitation products.
Integra LifeSciences competes with Smith+Nephew’s advanced wound management products through its Tissue Technologies business, which supplies tissue-repair and wound treatments. That business, rather than Integra’s larger neurosurgery-focused segment, is the sales line to watch for this rivalry.
MiMedx Group, Inc and Smith+Nephew compete in skin substitutes used to treat wounds, so reimbursement changes matter to both portfolios. Watch MiMedx’s U.S. wound-treatment sales as the cellular and tissue products market adjusts to reimbursement changes effective January 1, 2026.
MediWound Ltd.’s NexoBrid removes dead tissue from burns, while its chronic-wound pipeline challenges Smith+Nephew’s SANTYL ointment, which uses enzymes to remove damaged tissue. Watch progress on EscharEx and physician adoption if approved: SANTYL is the established enzymatic treatment it would have to displace in chronic wounds.
CONMED Corporation earningsCNMD
CONMED’s orthopedic surgery sales will show whether demand is holding up in markets that overlap with Smith+Nephew’s joint-repair and arthroscopic equipment businesses.
Watch CONMED’s orthopedic surgery sales and whether they move with its broader business. Growth in orthopedics would point to firmer demand in shared surgical markets, but would not by itself show that Smith+Nephew is losing share; weakness would flag softer demand facing Smith+Nephew’s joint-repair and arthroscopic equipment businesses.
MiMedx Group, Inc earningsMDXG
MiMedx’s U.S. wound-treatment sales will show whether demand for skin substitutes is under pressure as reimbursement rules change, a market that also matters to Smith+Nephew’s Advanced Wound Bioactives.
Watch the direction of MiMedx’s U.S. wound-treatment sales. Growth would show that buyers are still purchasing through the reimbursement changes, though it would not establish that Smith+Nephew is growing too. A decline would be consistent with weaker demand for skin substitutes and would flag similar market pressure for Smith+Nephew’s Advanced Wound Bioactives.
Stryker Corporation earningsSYK
Stryker’s orthopedics sales will show demand for joint-replacement and trauma products, where it competes with Smith+Nephew for hospitals’ and surgeons’ business.
Watch the direction of Stryker’s orthopedics sales. Growth would point to stronger demand in joint replacement and trauma, but would not prove Stryker is taking Smith+Nephew’s customers; a decline would suggest softer demand for Smith+Nephew’s orthopedic implants too. The conclusion is about the shared market’s demand, not which company is winning share.
Solventum Corporation earningsSOLV
Solventum’s wound-therapy sales will show how this competitor is faring in negative-pressure therapy and advanced dressings, products that overlap with Smith+Nephew’s wound devices.
Focus on Solventum’s wound-therapy products within MedSurg, not its total sales. Growth would show that this direct competitor is selling more, but sales alone cannot tell whether the market expanded or customers shifted to Solventum. A decline would show weaker sales in the overlapping business, not prove that Smith+Nephew won the orders. The report gauges competitor momentum, not Smith+Nephew’s market share.
